Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17761798 | 1.00 | CYP3A4 (0.37) | CYP3A4TSHRCYP1A2CYP2D6HSD17B10 | |
| SCHEMBL7305695 | 0.92 | BRD4 (0.38) | CYP3A4TSHRCYP1A2CYP2D6HSD17B10 | |
| SCHEMBL7305696 | 0.92 | BRD4 (0.38) | CYP3A4TSHRCYP1A2CYP2D6HSD17B10 | |
| SCHEMBL7305703 | 0.92 | BRD4 (0.38) | CYP3A4TSHRCYP1A2CYP2D6HSD17B10 | |
| SCHEMBL1225729 | 0.83 | GABRR1 (0.31) | — | |
| SCHEMBL8413192 | 0.82 | GABRR1 (0.39) | CYP1A2CYP2D6KMT2ACYP2C9CYP2C19 | |
| SCHEMBL1030622 | 0.82 | GABRR1 (0.39) | CYP1A2CYP2D6KMT2ACYP2C9CYP2C19 | |
| SCHEMBL1030623 | 0.82 | GABRR1 (0.39) | CYP1A2CYP2D6KMT2ACYP2C9CYP2C19 | |
| SCHEMBL1030281 | 0.82 | GABRR1 (0.39) | CYP1A2CYP2D6KMT2ACYP2C9CYP2C19 | |
| SCHEMBL14518649 | 0.82 | KMT2A (0.48) | CYP3A4TSHRCYP1A2CYP2D6HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723718-B2 | GLUTAMATERGIC ANTAGONIST AND AGONISTS; ANTIISCHEMIC AND ANTISPASMODIC AGENTS; BRAIN AND NERVOUS SYSTEM DISORDERS; TRAUMA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| US-20030158424-A1 | Substituted alpha, beta-anellated butyrolactones | STOLLE ANDREAS (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6462074-B1 | Substituted α, β-anellated butyrolactones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-1047684-B1 | SUBSTITUTED ALPHA,BETA-ANELLATED BUTYROLACTONES | BAYER AG (DE) | 2002-10-02 | — | — | EP | disclosed |
| US-6376539-B1 | ANTIISCHEMIC AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001004107-A1 | SUBSTITUTED α,β-ANELLATED BUTYROLACTONES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-18 | — | — | WO | disclosed |
| EP-1047686-A1 | SUBSTITUTED BICYCLIC LACTONES | Bayer Aktiengesellschaft (DE) | 2000-11-02 | — | — | EP | disclosed |
| EP-1047684-A1 | SUBSTITUTED ALPHA,BETA-ANELLATED BUTYROLACTONES | BAYER AG (DE) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999036416-A1 | SUBSTITUTED α,β-ANELLATED BUTYROLACTONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999036418-A1 | SUBSTITUTED BICYCLIC LACTONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158424-A1 | Substituted alpha, beta-anellated butyrolactones | GABRB2, GABRB3, GABRB1 | CYP3A4 1506/4885TSHR 4561/4885CYP1A2 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.